Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Oral administration of erythromycin decreases RNA toxicity in myotonic dystrophy
Masayuki Nakamori, Katarzyna Taylor, Hideki Mochizuki, et al.
Annals of Clinical and Translational Neurology (2015) Vol. 3, Iss. 1, pp. 42-54
Open Access | Times Cited: 60

Showing 1-25 of 60 citing articles:

Precise small-molecule cleavage of an r(CUG) repeat expansion in a myotonic dystrophy mouse model
Alicia J. Angelbello, Suzanne G. Rzuczek, Kendra McKee, et al.
Proceedings of the National Academy of Sciences (2019) Vol. 116, Iss. 16, pp. 7799-7804
Open Access | Times Cited: 103
Myotonic dystrophy: approach to therapy
Charles A. Thornton, Eric T. Wang, Ellie M. Carrell
Current Opinion in Genetics & Development (2017) Vol. 44, pp. 135-140
Open Access | Times Cited: 94
The myotonic dystrophy type 1 drug development pipeline: 2022 edition
Marta Pascual-Gilabert, Rubén Artero, Arturo López Castel
Drug Discovery Today (2023) Vol. 28, Iss. 3, pp. 103489-103489
Open Access | Times Cited: 37
Using Genome Sequence to Enable the Design of Medicines and Chemical Probes
Alicia J. Angelbello, Jonathan L. Chen, Jessica L. Childs‐Disney, et al.
Chemical Reviews (2018) Vol. 118, Iss. 4, pp. 1599-1663
Open Access | Times Cited: 78
Myotonic Dystrophy Type 1 Management and Therapeutics
Cheryl A. Smith, Laurie Gutmann
Current Treatment Options in Neurology (2016) Vol. 18, Iss. 12
Closed Access | Times Cited: 61
Myotonic dystrophy type 1 drug development: A pipeline toward the market
Marta Pascual-Gilabert, Arturo López Castel, Rubén Artero
Drug Discovery Today (2021) Vol. 26, Iss. 7, pp. 1765-1772
Open Access | Times Cited: 44
Myotonic dystrophy: candidate small molecule therapeutics
Piotr Konieczny, Estela Selma-Soriano, Anna Rapisarda, et al.
Drug Discovery Today (2017) Vol. 22, Iss. 11, pp. 1740-1748
Open Access | Times Cited: 49
Myotonic Dystrophies: A Genetic Overview
Payam Soltanzadeh
Genes (2022) Vol. 13, Iss. 2, pp. 367-367
Open Access | Times Cited: 24
Molecular Therapies for Myotonic Dystrophy Type 1: From Small Drugs to Gene Editing
Mariapaola Izzo, Jonathan Battistini, Claudia Provenzano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4622-4622
Open Access | Times Cited: 24
Reversal of RNA toxicity in myotonic dystrophy via a decoy RNA-binding protein with high affinity for expanded CUG repeats
Ludovic Arandel, Magdalena Matłoka, Arnaud F. Klein, et al.
Nature Biomedical Engineering (2022) Vol. 6, Iss. 2, pp. 207-220
Open Access | Times Cited: 23
Aberrant Myokine Signaling in Congenital Myotonic Dystrophy
Masayuki Nakamori, Kohei Hamanaka, James D. Thomas, et al.
Cell Reports (2017) Vol. 21, Iss. 5, pp. 1240-1252
Open Access | Times Cited: 48
Myotonic Dystrophies: Targeting Therapies for Multisystem Disease
Samantha LoRusso, Benjamin Weiner, W. David Arnold
Neurotherapeutics (2018) Vol. 15, Iss. 4, pp. 872-884
Open Access | Times Cited: 44
Reducing residual antibiotic levels in animal feces using intestinal Escherichia coli with surface-displayed erythromycin esterase
Minrui Liu, Pengya Feng, Apurva Kakade, et al.
Journal of Hazardous Materials (2020) Vol. 388, pp. 122032-122032
Closed Access | Times Cited: 38
Functions of the Muscleblind-like protein family and their role in disease
Hui Zhou, Jiachi Xu, Lijian Pan
Cell Communication and Signaling (2025) Vol. 23, Iss. 1
Open Access
Intrinsic Regulatory Role of RNA Structural Arrangement in Alternative Splicing Control
Katarzyna Taylor, Krzysztof Sobczak
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5161-5161
Open Access | Times Cited: 30
Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2
Lubov Timchenko
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10491-10491
Open Access | Times Cited: 17
Pentatricopeptide repeat protein targeting CUG repeat RNA ameliorates RNA toxicity in a myotonic dystrophy type 1 mouse model
Takayoshi Imai, Masahiro Miyai, Joe Nemoto, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 794
Closed Access
Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1
Marta López-Morató, J. David Brook, Marzena Wojciechowska
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 30
A Dimeric 2,9‐Diamino‐1,10‐phenanthroline Derivative Improves Alternative Splicing in Myotonic Dystrophy Type 1 Cell and Mouse Models
Jinxing Li, Masayuki Nakamori, Jun Matsumoto, et al.
Chemistry - A European Journal (2018) Vol. 24, Iss. 68, pp. 18115-18122
Closed Access | Times Cited: 30
Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple Mechanisms
Jana R. Jenquin, Leslie A. Coonrod, Quinn A. Silverglate, et al.
ACS Chemical Biology (2018) Vol. 13, Iss. 9, pp. 2708-2718
Open Access | Times Cited: 29
Exploring the Potential of Small Molecule-Based Therapeutic Approaches for Targeting Trinucleotide Repeat Disorders
Arun Kumar Verma, Eshan Khan, Sonali R. Bhagwat, et al.
Molecular Neurobiology (2019) Vol. 57, Iss. 1, pp. 566-584
Closed Access | Times Cited: 27
Combination Treatment of Erythromycin and Furamidine Provides Additive and Synergistic Rescue of Mis-splicing in Myotonic Dystrophy Type 1 Models
Jana R. Jenquin, Hongfen Yang, Robert W. Huigens, et al.
ACS Pharmacology & Translational Science (2019) Vol. 2, Iss. 4, pp. 247-263
Open Access | Times Cited: 24
Suppression of the yeast elongation factor Spt4 ortholog reduces expanded SCA36 GGCCUG repeat aggregation and cytotoxicity
Natsumi Furuta, Setsuki Tsukagoshi, Kimitoshi Hirayanagi, et al.
Brain Research (2019) Vol. 1711, pp. 29-40
Closed Access | Times Cited: 20
Precise Targeted Cleavage of a r(CUG) Repeat Expansion in Cells by Using a Small-Molecule–Deglycobleomycin Conjugate
Alicia J. Angelbello, Mary E. DeFeo, Christopher M. Glinkerman, et al.
ACS Chemical Biology (2020) Vol. 15, Iss. 4, pp. 849-855
Open Access | Times Cited: 20
Molecular mechanisms and therapeutic strategies for neuromuscular diseases
Alberto A. Zambon, Falzone Yuri Matteo, Bolino Alessandra, et al.
Cellular and Molecular Life Sciences (2024) Vol. 81, Iss. 1
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top